Salarius Pharmaceuticals Inc.
13F holders, Q2 2025 (June 30)14holders +5
6new positions
1sold out
$0.89avg. 13F price*
At the end of Q2 2025, 14 institutions reported holding Salarius Pharmaceuticals Inc. in their 13F filings, up 5 from Q1 2025. 6 opened new positions and 1 sold out. The largest holders were HRT Financial LP ($28K), UBS Group AG ($16K) and Cubist Systematic Strategies, LLC ($15K).
- Company
- Salarius Pharmaceuticals Inc.
- CUSIP
- 79400X404
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $70K |
| Exits | 1 | $12K |
All 13F filers, Q1 2025 → Q2 2025: 83,441 shares bought and 31,125 shares sold, net +52,316 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 14 holders
| HRT Financial LP | 0.00% | New | 31,676 | $28K |
| UBS Group AG | 0.00% | Reduce -46.4% | 18,138 | $16K |
| Cubist Systematic Strategies, LLC | 0.00% | New | 16,727 | $15K |
| Goldman Sachs Group Inc. | 0.00% | New | 16,667 | $15K |
| Geode Capital Management, LLC | 0.00% | Add +35.3% | 15,560 | $14K |
| Barclays PLC | 0.00% | New | 8,024 | $7K |
| Citigroup Inc. | 0.00% | New | 5,889 | $5K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +10.0% | 3,663 | $3K |
| Elevation Point Wealth Partners, LLC | 0.00% | New | 61 | $55 |
| Osaic Holdings, Inc. | 0.00% | Reduce -63.6% | 59 | $52 |
| Bank of America Corp. | 0.00% | Add +50.0% | 18 | $16 |
| Morgan Stanley | 0.00% | No change | 7 | $6 |
| SBI Securities Co., Ltd. | 0.00% | No change | 1 | $1 |
| BlackRock, Inc. | 0.00% | No change | 1 | $1 |
"% of holder's portfolio" is SALARIUS PHARMACEUTICALS INC's weight in each manager's 13F, not the share of Salarius Pharmaceuticals Inc. the manager owns.